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Abstract
Background: Soluble biglycan (sBGN) and soluble decorin (sDCN), are two closely related essential components of
extracellular matrix which both have been shown to possess proinflammatory properties. We studied whether sBGN
or sDCN were present in synovial fluid (SF) of osteoarthritis (OA) or rheumatoid arthritis (RA) patients and studied
sBGN or sDCN potential role in the degradation of OA cartilage.
Methods: SF obtained from meniscus tear, OA, and RA patients were analysed for sBGN and sDCN using enzyme-linked
immunosorbent assays. OA chondrocytes and cartilage explants were stimulated for 48 h with 5 μg/ml sBGN or 1 μg/ml
lipopolysaccharide. Messenger RNA (mRNA) levels of Toll-like receptors (TLRs), proteinases and cartilage matrix molecules
were determined using quantitative real-time polymerase chain reaction. Protein levels of matrix metalloproteinases
(MMPs) and cytokines were measured using Luminex xMap technology. Production of nitric oxide (NO), release of
proteoglycans and soluble collagen were measured from conditioned culture media using biochemical assays. OA
cartilage explant proteoglycans were stained for Safranin O and quantified using image analysis. TLR4 activation by sBGN
and sDCN was studied in engineered HEK-293 cells with TLR4 signalling genes inserted together with a reporter gene.
Results: sBGN was found in meniscus tear SF (14 ± 2 ng/ml), OA SF (582 ± 307 ng/ml) and RA SF (1191 ± 482 ng/ml).
Low levels of sDCN could also be detected in SF of meniscus tear (51 ± 4) ng/ml, OA (52 ± 3 ng/ml), and RA (49 ± 4 ng/ml).
Stimulation of chondrocytes with sBGN increased significantly the mRNA and protein expression of catabolic MMPs,
including MMP1, MMP9 and MMP13, and of inflammatory cytokines interleukin (IL)-6 and IL-8, whereas the expression
of anabolic markers aggrecan and collagen type II was decreased. sBGN induced release of proteoglycans, collagen
and NO from chondrocytes and cartilage explants. The catabolic response in explants was dependent of OA cartilage
degradation stage. The mechanism of action of sBGN was mainly mediated through the TLR4-nuclear factor-κB
pathway.
Conclusions: High levels of sBGN was found in advanced OA and RA SF. sBGN activates chondrocytes mainly via TLR4,
which results in net loss of cartilage. Thus, sBGN can be a mediator of OA cartilage degradation and also a potential
biomarker for arthritis.
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Background
Osteoarthritis (OA) is among the top five leading causes
of disability worldwide [1]. To date, no effective long-
term disease-modifying treatment for OA is available. At
the root of the OA burden lies poor comprehension of
the molecular pathophysiology of pre-symptomatic and
clinically symptomatic OA.
Cartilage degeneration, a hallmark of OA, has its onset
in wear, tear and mechanical injuries of the joint cartil-
age. Although trauma is perhaps the first causal event in
OA, the host inflammatory response plays an important
role in the pathogenesis OA and inflammation is be-
lieved to be the major driver to symptomatic OA [2, 3].
Cells of the cartilage, known as chondrocytes, maintain
cartilage tissue homeostasis. They control the structural
assembly of extracellular matrix (ECM) and regulate de-
structive, remodelling and reparative processes [4]. In OA,
cartilage-resident chondrocytes produce proteinases such
as aggrecanases (ADAMTS-4, ADAMTS-5), matrix me-
talloproteinases (e.g., MMP-13 and MMP-9) and cathep-
sin K, and the anabolic synthesis of structural molecular
components aggrecan and collagen type II (Col-II) are
compromised [5]. Such a metabolic imbalance results in a
failure of cartilage homeostasis and pathological cartilage
destruction as well as eventual loss of cartilage.
ECM molecules have been thought to function as
purely structural matrix-bound components, but evi-
dence is emerging that they can also function as soluble
ligands for pattern-recognising danger signalling recep-
tors, mainly for Toll-like receptors (TLRs) [6–8]. Several
of the ECM molecules found in OA joint and synovial
fluid (SF) have been shown to trigger catabolic responses
in TLR-equipped OA chondrocytes [9–11]. Biglycan
(BGN) and decorin (DCN) are two small, closely related
structural proteoglycans with leucine-rich repeats (small
leucine-rich proteoglycan, SLRP) [12, 13]. The soluble
forms of BGN (sBGN) or (sDCN) released from the car-
tilage matrix as a result of tissue injury could potentially
function as an endogenous danger signal [14]. For ex-
ample, sBGN, the size of which is approximately 95 kDa,
has been shown trigger TLR4/TLR2 signalling in human
aortic valve and in acute ischemic kidney, as well as to
activate the NLRP3 inflammasome in macrophages
[15–17]. sDCN has been shown to activate TLR4/
TLR2 signalling in macrophages [18].
We hypothesised that BGN is a prototypic example of
a major essential cartilage ECM component. Upon re-
lease from stressed cartilage, it might activate TLR-
mediated catabolic signalling pathways [19, 20]. In fact,
several studies have shown that de novo BGN and DCN
synthesis is increased in OA, that BGN and DCN frag-
ments are produced and released by ADAMTSs and
MMPs, and that OA SF also contains BGN and DCN
autoantibodies [21–25]. However, to our knowledge, no
studies have addressed the concentration of intact sBGN
and sDCN in OA or rheumatoid arthritis (RA) SF or in-
cluded examination of the eventual direct role of these
proteoglycans in chondrocyte-mediated cartilage degrad-
ation in OA.
Our aim was to study whether sBGN and sDCN can
be found in SF from arthritic joints and whether sBGN
and sDCN can contribute to cartilage degradation by ac-
tivating the TLR-mediated catabolic signalling in primary
OA chondrocytes and OA tissue explants.
Methods
Tissue acquisition, cartilage explant culture and primary
chondrocyte culture
Patient recruitment and participation and sample collec-
tion were approved by the Helsinki and Uusimaa Hospital
District ethics committee (Dnr_59/13/03/02/2013) and
hospital board of directors (9310/407), and signed in-
formed consent was obtained from the patients. Samples
were collected from patients with OA who underwent
total knee arthroplasty (TKA) (N = 12). Half of the pa-
tients were women. The mean age of the patients was
63.5 years (range 53–73). Tibial plateau containing cartil-
age and subchondral bone was cut off to provide space for
the tibial component of the TKA implant. Tibial plateau
samples were collected into sterile sample containers con-
taining cold phosphate-buffered saline solution (PBS) and
processed within 2 h.
Before tissue samples were harvested, the macroscopic
appearance of the visible pathological changes in differ-
ent sampling areas was recorded according to the
arthroscopic grading scale of Société Française d’Ar-
throscopie [26]. Explant samples were collected from
two different types of areas: grade I OA samples with no
macroscopically visible lesions (which represents early
OA cartilage degradation stages) or grade IV samples
with full-thickness osteochondral lesions [27]. This grading
of the samples makes possible a stratified analysis based on
the degree of OA cartilage, from very mild to severe. Cylin-
drical full-thickness cartilage explants were obtained from
graded tibial plateau areas using a 4-mm circular punch
biopsy blade (Kai Medical, Oyana, Japan). Explants were
cultured in Gibco Dulbecco’s modified Eagle’s medium
(DMEM)/F-12 (Life Technologies, Carlsbad, CA, USA)
supplemented with 10 % foetal calf serum (FCS) for 24 h
before stimulation.
When cartilage explants were not isolated, cartilage
tissue (with bone cut away) was used for chondrocyte
isolation. Chondrocytes form only 1–3 % of the volume
of the cartilage, so the whole cartilage was used for
chondrocyte isolation to obtain enough cells. This means
that the chondrocytes represent a heterogeneous popula-
tion of OA chondrocytes. This does not allow a stratified
analysis. Cartilage specimens were sequentially digested
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in 2.5 mg/ml pronase and 250 mg/ml collagenase P
(Roche, Basel, Switzerland), with a PBS wash in between,
for 60 minutes and overnight, respectively, under slow agi-
tation at 37 °C. The resulting cell suspension was filtered
through a 70-μm nylon cell strainer, centrifuged, washed
twice with PBS and seeded at 1.5 × 105/cm2 in Gibco
DMEM/F-12 supplemented with 10 % FCS, 100 U/ml
penicillin, 100 U/ml streptomycin and 0.25 μg/ml ampho-
tericin B (Life Technologies). Cells were balanced for 3–4
days before stimulation. For cryopreservation, cells were
suspended in FCS containing 10 % (vol/vol) dimethyl
sulphoxide and frozen in an isopropanol container for
24 h at −80 °C before storage in liquid nitrogen.
Arthritis group definitions for synovial fluid collection
Early osteoarthritis
SF samples were collected from ten patients scheduled for
arthroscopic surgery. The main indication for surgery was
a suspicion of a meniscal tear. Patients with inflammatory
arthritis, severe arthritis, corticosteroid injection within
6 weeks, blood dyscrasias or active malignancy were ex-
cluded. The prior use of nonsteroidal anti-inflammatory
drugs was not considered an exclusion criterion. The diag-
nosis of early arthritis was made during arthroscopy and
based on the presence of minimal visible chondral lesions.
Advanced osteoarthritis
SF samples were collected from ten patients scheduled
for elective total knee replacement for management of
primary idiopathic OA. The exclusion criteria were simi-
lar to those for patients with early OA.
Rheumatoid arthritis
SF samples were collected from ten patients with RA diag-
nosed fulfilling the American College of Rheumatology/
European League Against Rheumatism classification cri-
teria for RA [28].
Synovial fluid sample collection
Patients with early OA, advanced OA and RA were, de-
pending on the schedule of the surgeon, randomly se-
lected for collection of SF samples via needle aspiration
before opening of the joint. Blood-contaminated samples
were excluded. SF maintained at 4 °C was aliquoted
within 2 h into sterile Eppendorf tubes, centrifuged at
1200 g for 5 minutes at room temperature to separate
solid debris and cells from the fluid phase, snap-frozen
in liquid nitrogen and stored at −80 °C. When first
thawed, SF was treated with a protease inhibitor cocktail
(Roche Diagnostics, Meylan, France).
Enzyme-linked immunosorbent assay
SF was measured for intact-only sBGN and DCN molecules
using a specific sandwich enzyme-linked immunosorbent
assay (ELISA) (Uscn Life Science Inc., Hubei, China, and
BioVendor Laboratorní medicína, Brno, Czech Republic,
respectively) for detection of intact sBGN and sDCN mole-
cules. BGN and DCN fragments are not detected by the
immunoassays. Absorbance was measured at 450 nm, as
well as 450 nm and 630 nm, for sBGN and sDCN immuno-
assays, respectively. All measurements were performed in
duplicates.
SEAP NF-κB activity assays
TLR4 activity was measured using a cell-based assay
according to the manufacturer’s instructions (InvivoGen,
San Diego, CA, USA). HEK-hTLR4 cells express TLR4
and MD-2/CD14 co-receptor genes of human origin and
contain the secreted embryonic alkaline phosphatase
(SEAP) reporter gene for monitoring nuclear factor
(NF)-κB activation. Upon interaction with the appropri-
ate ligand, TLR4 transduces a signal which results in
NF-κB activation and the expression of secreted alkaline
phosphatase (AP), which can be detected by using detec-
tion medium (QUANTI-Blue, a medium used for the de-
tection and quantification of secreted AP; InvivoGen)
and measured with a spectrophotometer.
Briefly HEK-hTLR4 cells were cultured at a density of
2.5 × 104 cells in 96-well plates and maintained in complete
DMEM with selective antibiotics, as described in the manu-
facturer’s instructions (InvivoGen). Cells were then stimu-
lated with 5 μg/ml BGN (Sigma-Aldrich, St. Louis, MO,
USA), 8 μg/ml sDCN (R&D Systems, Minneapolis, MN,
USA) or 1 μg/ml lipopolysaccharide (LPS) (positive control)
for 24 h, and activation of TLR4 and NF-κB signalling was
analysed by measuring SEAP from conditioned culture
medium samples according to the manufacturer’s instruc-
tions (InvivoGen).
Stimulation of chondrocyte and cartilage explant cultures
Primary chondrocytes cultures from passage 1 were
stimulated for 24 or 48 h with 5 μg/ml bovine BGN
(high sequence homology and structural conservation
with human BGN) obtained from articular cartilage and
solubilised according to the manufacturer’s instructions
(Sigma-Aldrich) [29]. BGN endotoxin (LPS) contamin-
ation was not detected using the limulus amebocyte
lysate test. As additional endotoxin controls, 5 μg/ml
sBGN was incubated in fresh Gibco DMEM/F-12 contain-
ing 50 μg/ml proteinase K (Thermo Scientific, Waltham,
MA, USA) or 25 μg/ml polymyxin B (InvivoGen) at 37 °C
for 1 h, after which the mixtures were added to the pri-
mary chondrocyte cultures. Protein homogeneity was con-
firmed by sodium dodecyl sulphate–polyacrylamide gel
electrophoresis and Coomassie staining (performed by
the manufacturer). LPS (Sigma-Aldrich) stimulation at
1 μg/ml was used as a positive TLR2/TLR4 control. In se-
lected experiments, 1 μM CLI-095 (InvivoGen) was added
Barreto et al. Arthritis Research & Therapy  (2015) 17:379 Page 3 of 15
to primary chondrocyte cultures 30 minutes before sBGN
or LPS. CLI-095, also known as TAK-242, specifically sup-
presses TLR4 signalling mediated by the intracellular do-
main of the receptor. Further receptor-blocking studies
were performed with the addition of 20 μg/ml TLR2
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) or
20 μg/ml TLR4 (Santa Cruz Biotechnology) for 1 h before
the addition of sBGN at 5 μg/ml.
The optimal concentration for sBGN stimulation was
determined in 24- and 48-h pilot experiments using
0.05, 0.5 and 5 μg/ml of sBGN, followed by analysis of
MMP13, CTSK (cathepsin K, cat K), IL6 (interleukin-6,
or IL-6) and COL2A1 (collagen type II α chain 1, or Col-
IIA) gene messenger RNA (mRNA) copy numbers rela-
tive to the TATA box-binding protein (TBP) house-
keeper, by using quantitative real-time polymerase chain
reaction (qRT-PCR). Cartilage explant cultures were
stimulated using the same conditions.
Real-time polymerase chain reactions
Total RNA was isolated from cartilage explants by using
the RNAqueous® kit (Thermo Scientific) and from primary
chondrocytes by using the RNeasy® Mini Kit (Qiagen, Val-
encia, CA, USA). Relative quantification of the gene levels
was performed by comparing the cycle threshold (Ct)
values of the different genes, correcting for glyceraldehyde
3-phosphate dehydrogenase (GAPDH) and TBP content
(ΔCt) and for non-stimulated conditions (ΔΔCt) and fi-
nally expressed as fold changes. Primer sequences are pro-
vided in Table 1.
Protein measurements using Luminex xMAP® technology
Measurement of protein levels was done using xMAP®
technology (Luminex, Austin, TX, USA). To determine
protein levels of MMPs (MMP-1, MMP-3, MMP-9 and
MMP-13) as well as cytokines and chemokines (IL-6, IL-
8) in chondrocyte culture supernatant, xMAP® technology
on the Bio-Plex 200® system (Bio-Rad Laboratories,
Hercules, CA, USA) was used in combination with multi-
plex MMP/cytokine kits (ProcartaPlex; eBioscience; San
Diego, CA, USA). Protein levels were measured in 25 μl of
culture medium (diluted 1:2).
Measurement of nitric oxide
Nitric oxide (NO) was measured from conditioned culture
medium samples using a nitrate/nitrite colorimetric assay
kit (Cayman Chemical, Ann Arbor, MI, USA). Nitrate was
converted to nitrite by adding nitrate reductase and its co-
factor, followed by the addition of Griess reagent to de-
velop a deep purple colour. The absorbance was measured
at 544 nm using a plate reader (Chameleon; Hidex, Turku,
Finland).
Measurement of soluble sulphated glycosaminoglycans
and soluble collagen type II
Soluble sulphated glycosaminoglycan (sGAG) standards,
blanks and conditioned culture medium samples were
mixed with the sGAG-binding Blyscan Dye Reagent® for
30 minutes, followed by separation of the GAG–dye com-
plex by centrifugation and dissociation of the dye from the
pellet (Biocolor Ltd., Carrickfergus, UK). Soluble Col-II
Table 1 Primer pairs used for real-time polymerase chain reactions
Gene Protein name Primer sequence
ADAMTS4 A disintegrin and metalloproteinase with thrombospondin motifs 4 Forward: 5′-AAT CCT GTC AGC TTG GTG GT-3′
Reverse: 3′-CTT GGA GTT GTC ATG GAG CA-5′
ADAMTS5 A disintegrin and metalloproteinase with thrombospondin motifs 5 Forward: 5′-CTT CAC TGT GGC TCA CGA AA-3′
Reverse: 3′-AAT GTC AGG TTG CAC TGC TG-5′
MMP13 Matrix metalloproteinase 13 (MMP-13) Forward: 5′-CTA TGG TCC AGG AGA TGA AG-3′
Reverse: 3′-AGA GTC TTG CCT GTA TCC TC-5′
CTSK Cathepsin K Forward: 5′-ACC CAA CAG GCA AGG CAG CTAA-3′
Reverse: 3′-GCA ATG CCA CAGG CGT TGT TCT-3′
MMP9 Matrix metalloproteinase 9 (MMP-9) Forward: 5′-TTC TCC AGA AGC AAC TGT CC-3′
Reverse: 3′-CGG CAA GTC TTC CGA GTA GT-5′
ACAN Aggrecan Forward: 5′-TGG TGA TGA TCT GGC ACGA-3′
Reverse: 3′-TCT GCG TTT GTA GGT GGTG-5′
COL2A1 Collagen, type II, alpha 1 Forward: 5′-GAG TCA AGG GTG ATC GTG GT-3′
Forward: 5′-AAG CAC CTT GGT CTC CAG AA-5′
TBP TATA box-binding protein Forward: 5′-GAA GAA CAA TCC AGA CTA GCA GCA-3′
Reverse: 3′-CCT TAT AGG GAA CTT CAC ATC ACAG-5′
GAPDH Glyceraldehyde 3-phosphate dehydrogenase Forward: 5′-AAG GTC ATC CCT GAG CTG AA-3′
Reverse: 3′-TGC TGT AGC CAA ATT CGT TG-5′
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was similarly mixed with the collagen-binding Sircol Dye
Reagent® (Biocolor Ltd.) for 30 minutes, followed by cen-
trifugation, pelleting, washes with salt wash reagent, cen-
trifugation and dissociation of the collagen–dye complex
using an alkali reagent vortexing wash. Absorbance was
measured at 595 and 540 nm, respectively, using a plate
reader (Chameleon).
Safranin O staining
Control and sBGN-stimulated cartilage explants were
fixed in neutral buffered 10 % formalin for 2 weeks be-
fore dehydration in ethanol series, clearing in xylene and
embedding in paraffin. Deparaffinised tissue sections
were stained with Fast Green dye, rinsed in 1 % acetic
acid and stained in 0.1 % Safranin O before evaluation
using a Nikon LV-DIA Base microscope (Nikon Instru-
ments, Tokyo, Japan) with a motorized XY staging sys-
tem (OptiScan III; Prior Scientific, Rockland, MA, USA)
connected to a DS-Fi1 digital camera (Nikon Instru-
ments) using NIS-Elements Basic Research analysis
(Nikon Instruments). Image analysis was done using
ImageJ software (National Institutes of Health, Bethesda,
MD, USA).
Statistical analysis
Differences between groups were tested using the
Mann–Whitney U test, the Wilcoxon signed-rank test
or Student’s t test, as appropriate. Effects of covariates
were analysed by multiple linear regression. All statis-
tical analysis were performed using IBM SPSS version 21
software (IBM, Armonk, NY, USA). p Values <0.05 were
considered significant.
Results
sBGN and sDCN can be found in synovial fluid obtained
from patients with OA or RA
BGN and DCN are key components of the cartilage
matrix. We hypothesised that some intact BGN or DCN
could be released from matrix into SF in OA or RA and
that in soluble form they could act as a proinflammatory
stimulus. Indeed, sandwich ELISA disclosed clearly higher
sBGN levels in advanced OA (582 ± 307 ng/ml) than the
levels found in patients with meniscus tear who had very
early OA (14 ± 2 ng/ml) (Table 2). The highest levels of
sBGN were observed in SF obtained from patients with
RA (1191 ± 482 ng/ml) (Table 2). In contrast to sBCN, the
SF levels of sDCN were low, and no differences were ob-
served between early OA (51 ± 4 ng/ml), OA (52 ± 3 ng/ml)
and RA: (49 ± 4 ng/ml). Covariates (age, sex and body mass
index) tested with multiple linear regression models were
not associated with SF sBGN or SF sDCN levels.
sBGN upregulates catabolic factors in OA chondrocytes
As high concentrations of intact sBGN were found in
the SF of OA and RA patients, we studied whether
sBGN could have effects on the cartilage metabolism.
First, we studied the effect of sBGN on the expression of
catabolic cartilage factors. In primary monolayer chon-
drocytes, sBGN significantly increased gene expression
of ADAMTS4, ADAMTS5, MMP13, CTSK and MMP9
almost as efficiently as LPS (Fig. 1a). Studies of cartilage
explant tissues obtained from patients with varying de-
grees of OA severity revealed that the response to sBGN
was dependent on the grade of cartilage degradation.
sBGN induced pronounced expression of catabolic
factors in grade I OA cartilage, whereas a more modest
increase of catabolic factors was observed in highly
degenerated grade IV OA cartilage (Fig. 1b).
To further assess whether the studied gene mRNA
transcripts were also translated into proteins, we used
Luminex xMAP® technology. In cell culture superna-
tants, the levels of MMP-1 and MMP-3 were substan-
tially upregulated (1.6- and 3.6-fold, respectively) by
sBGN compared with unstimulated controls (Fig. 2).
Compared with positive control LPS, the effects of
sBGN on protein levels for MMP-1, MMP-3, MMP-9
and MMP-13 were 3 %, 50 %, 82 % and 21 %, respect-
ively, of that of LPS (LPS data not shown).
Levels of proinflammatory cytokines IL-6 and IL-8
were also upregulated by sBGN compared with unstimu-
lated control (1.4- and 2.2-fold, respectively) (Fig. 2).
Compared with LPS, the effects of sBGN on cytokine
Table 2 Intact sBGN and sDCN concentration levels in synovial fluid obtained from knee joints of early osteoarthritis, advanced
osteoarthritis and rheumatoid arthritis patients
Characteristics Early OA (n = 10) Advanced OA (n = 10) RA (n = 10)
Patient age, yr 63.1 ± 16 64.4 ± 10 55.3 ± 15.4
Males 40 (4) 40 (4) 30 (3)
Body mass index, kg/m2 27.2 ± 4.4 27.8 ± 3.5 24.3 ± 4.7
sBGN, ng/ml 14 ± 2 582 ± 307a 1191 ± 482a
sDCN, ng/ml 51 ± 4 52 ± 3 49 ± 4
OA osteoarthritis, RA rheumatoid arthritis, sBGN soluble biglycan, sDCN soluble decorin
Data are presented as mean ± SD or count (%)
ap < 0.01 by Student’s t test
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Fig. 1 Effect of soluble biglycan (sBGN) on the expression of proteinases associated with matrix remodelling and cartilage degeneration in
osteoarthritis (OA). a In primary chondrocytes, sBGN increased all proteinases examined. Lipopolysaccharide (LPS) was used as a positive control.
b In cartilage explants, sBGN increased ADAMTS5, MMP13, CTSK and MMP9 messenger RNA (mRNA) only in mild grade I OA and not in severe
grade IV OA. The results are expressed as fold changes (mean ± SD) relative to TATA box-binding protein (TBP) housekeeper and compared with
non-stimulated controls. Samples were run as technical duplicates, and each experiment was done using samples obtained from at least six different
donors (biological replicates). *p< 0.05, **p< 0.01, ***p< 0.001 vs. non-stimulated controls; ##p< 0.01 for pairwise comparisons between mild grade I OA
and severe grade IV OA. ADAMTS a disintegrin and metalloproteinase with thrombospondin type 1 motif (aggrecanase), MMP matrix metalloproteinase,
CTSK cathepsin K
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levels for IL-6 and IL-8 were 18 % and 25 %, respectively
(LPS data not shown).
sBGN impairs the synthesis of major cartilage matrix
components in OA chondrocytes
To determine the effect of sBGN on overall cartilage
turnover, we studied the effect of sBGN on the anabolic
functions of OA chondrocytes. In primary OA chondro-
cytes, sBGN significantly inhibited aggrecan and Col-II
mRNA expression (Fig. 3a). The studies on cartilage ex-
plants revealed that sBGN significantly decreased Col-II
mRNA expression in highly degenerated grade IV OA
but had no significant effect on the expression in grade I
OA cartilage (Fig. 3b).
sBGN increases proteoglycan and collagen release from
cartilage explants
Release of proteoglycans and soluble collagen from cartilage
explants into cell culture media was determined to confirm
that sBGN can also induce the degradation of OA cartilage
by catabolic chondrocytes in situ. sBGN induced prominent
release of sGAG in grade I OA explants, whereas sBGN-
induced collagen release was observed only in grade IV OA
cartilage (Fig. 4). Proteoglycan release was further con-
firmed by Safranin O staining in sBGN-treated cartilage ex-
plants. sBGN decreased the total quantity of proteoglycan
in explants by approximately 50 % (Fig. 5).
sBGN upregulates TLR4 expression in chondrocytes and
in cartilage tissue explants
To study the mechanism of the effects of sBGN on cartilage
metabolism, the effects of sBGN on TLR expression and
function were first studied. Expression of TLR2 and TLR4
mRNA was observed in primary monolayer chondrocytes
and cartilage explants of all patients with OA. In accord-
ance with earlier studies, basal TLR2/TLR4 levels were
slightly (1.3-fold) higher in grade IV OA than in grade I OA
[30]. In primary monolayer chondrocyte cultures, sBGN
significantly increased TLR4 expression but did not have
any significant effect on TLR2mRNA expression (Fig. 6a).
Studies of cartilage explants revealed that the TLR re-
sponse to sBGN is dependent on the grade of cartilage
degradation. In grade I OA, the sBGN-induced increase
of TLR4 mRNA expression was 352 % than that ob-
served in grade IV OA cartilage (Fig. 6b). In contrast,
there was no difference in sBGN-induced TLR2 mRNA
expression between grade I and grade IV OA (Fig. 6b).
Blocking TLR4 by using a low molecular weight inhibi-
tor of TLR4 signalling (CLI095) abrogated the sBGN-
induced increase of TLR4 mRNA expression (Fig. 7a).
Catabolic effect of sBGN in articular chondrocytes is
mediated via TLR4
Inducible nitric oxide synthase (iNOS) is activated via
TLR2/TLR4/NF-κB pathway activation. To further evaluate
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(IL)-6 and IL-8 proteins. sBGN leads to the upregulation chondrocyte-mediated production of major catabolic markers known in osteoarthritis.
sBGN-induced concentration levels compared with controls did not reach the statistical significance level <0.05. The results are expressed mean ±
SD. Samples were run as technical duplicates, and each experiment was done using samples from three different donors (biological replicates)
Barreto et al. Arthritis Research & Therapy  (2015) 17:379 Page 7 of 15
Soluble collagen - explants
B
s (5 µg/ml)BGN
re
le
as
ed
so
lu
bl
e
c o
lla
ge
n
(µ
g/
m
g
ti
ss
ue
)
Grade IV OAGrade I OA
0.0
2.0
4.0
6.0
8.0
10.0
12.0
Control
Sulphated glycosaminoglycans - explants
A
re
le
as
ed
(µ
g/
m
g
ti
ss
ue
)
G
A
G
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
Grade IV OAGrade I OA
*
*
#
Fig. 4 Effects of soluble biglycan (sBGN) on release of glycosaminoglycans (GAGs) and soluble collagen from cartilage explants compared with
non-stimulated controls. a In grade I osteoarthritis (OA), sBGN increased GAG release. b In grade IV OA, sBGN increased collagen release. The
results are presented as mean ± SD. Samples were run as technical duplicates, and each experiment was done using samples from at least six
different donors (biological replicates). *p < 0.05 vs. non-stimulated controls; ##p < 0.01 for pairwise comparisons between mild grade I OA and
severe grade IV OA
matrix molecules m -  primaryRNA
chondrocytes
A
-2.5
-2
-1.5
-1
-0.5
0
ACAN COL2A1
*
*F
ol
ds
of
ch
an
ge
matrix molecules m -  explantsRNA
F
ol
ds
of
ch
an
ge
B
-35
-20
-5
10
25
40
55
70
C
O
L
2A
1
A
C
A
N
*
*
*
##
s (5 µg/ml)BGN LPS (1 µg/ml)Control Grade I OA Grade IV OAControl
Fig. 3 Effects of soluble biglycan (sBGN) on the expression of aggrecan and collagen type II (Col-II). a In primary chondrocytes, sBGN decreased
aggrecan and Col-II. Lipopolysaccharide (LPS) was used as a positive control. b In cartilage explants, sBGN did not affect aggrecan (ACAN) or Col-
II(COL2A1) in grade I osteoarthritis (OA) but decreased Col-II(COL2A1) in grade IV OA, with a different response in mild and severe OA. The results
are expressed as fold changes (mean ± SD) relative to the TATA box-binding protein (TBP) housekeeper and compared with non-stimulated con-
trols. Samples were run as technical duplicates, and each experiment was done using samples obtained from at least six different donors (biological
replicates). *p < 0.05 vs. non-stimulated controls; ##p < 0.01 for pairwise comparisons between mild grade I OA and severe grade IV OA. mRNA
messenger RNA
Barreto et al. Arthritis Research & Therapy  (2015) 17:379 Page 8 of 15
the role of TLRs in sBGN-induced signalling, we studied
the effect of sBGN on NO release from primary OA chon-
drocytes. In primary OA chondrocyte cultures, sBGN sig-
nificantly increased NO production (Fig. 8a). In cartilage
explant tissues, sBGN increased NO production slightly
more in grade I OA than in grade IV OA (Fig. 8b). Blocking
of TLR4 signalling with TLR4-neutralising antibody or syn-
thetic inhibitor CLI-095 significantly reduced NO produc-
tion to levels observed in non-stimulated controls (Fig. 8c),
suggesting that the effect of sBGN is mediated via TLR4.
To exclude the effect of contaminating LPS, polymyxin B
was added, which had no effect on the sBGN-induced
production of NO. In contrast, proteinase K reduced
NO production to levels of non-stimulated controls, fur-
ther supporting the finding that the observed effect of
sBGN is not caused by LPS contamination. Moreover,
blocking of TLR4 signalling abrogated the increase in
mRNA expression of the catabolic factors induced by both
sBGN and LPS while also restoring to normal the levels of
the mRNA expression of the key anabolic factors ACAN
and COL2A1 (Fig. 7b and c). In contrast to TLR4, TLR2-
neutralising antibody had no significant effect on NO
production. Together, these above suggest that the ef-
fect of sBGN on cartilage metabolism is mediated via
activation of TLR4 and that TLR2 has either no or
only a minor role.
To confirm that sBGN signalling is mediated through
TLR4/NF-κB pathway, we studied the activation of NF-
κB after stimulation with sBGN. This was done using
engineered HEK-hTLR4 cells, which can be stimulated
only through activation of the TLR4 receptors. These
cells have been stably transfected with SEAP plasmid
containing NF-κB response elements, and the activation
of NF-κB can be monitored by measuring activity of
Fig. 5 Effects of soluble biglycan (sBGN) on proteoglycan content in osteoarthritis (OA) cartilage explants from five different patients. a Safranin O
staining of the formalin-fixed, paraffin-embedded tissue sections produced from the OA cartilage explants (4 mm) after 48-h incubation. Note
extensive proteoglycan depletion in all samples. Safranin O photomicrographs are panoramic images constructed from several photomicrographs
to provide an overall view of cartilage explant extent in one image. Original magnification, ×20. b Proteoglycan depletion was quantified by
optical density of Safranin O staining using ImageJ image analysis software. The results are presented as mean ± SD. Proteoglycan content was
reduced by 50 ± 20 % compared with non-stimulated samples. **p < 0.01
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SEAP. Stimulation of HEK-hTLR4 cells with sBGN
caused a substantial increase of SEAP, while inhibition
of TLR4 signalling with TLR4 inhibitor CLI-095 pre-
vented the increase of SEAP levels. sDCN and LPS
caused a similar increase of SEAP levels. Proteinase K
abrogated SEAP upregulation by sBGN and sDCN, while
polymyxin B did not alter the response, thus ensuring
that the studied effect was not caused by endotoxin con-
tamination (Fig. 8d).
Discussion
BGN and DCN are two major non-collagenous SLRP
products of chondrocytes which are deposited into ar-
ticular cartilage matrix [13]. In this study, we show, for
the first time to our knowledge, that intact sBGN is
present in SF obtained from patients with meniscus tear
lesions and early OA, advanced OA or RA, with the
highest concentrations found in advanced OA and RA.
DCN could also be found in SF, but, in contrast to BGN,
only low levels were detected and no differences be-
tween early OA, advanced OA and RA were observed.
Thus, matrix-embedded chondrocytes as well as other
cells in joints are exposed to fluid phase sBGN and
sDCN. Intact sBGN and sDCN, but not their fragments,
have been shown to engage proinflammatory responses
[31, 32]. Therefore, while BGN fragments are known to
be released into the SF of patients with OA, their
presence is merely a reflection of disease activity. Hence,
they have been proposed to be solely a diagnostic bio-
marker. The observed increased levels of intact sBGN
are also in line with the observed upregulation of mRNA
and protein levels of sBGN in human OA cartilage tissue
and also in cartilage obtained using a sheep meniscec-
tomy animal model of OA. Although DCN mRNA and
protein levels have been shown to increase in OA, this
was not reflected in the level of DCN in SF [22, 25, 33].
Interestingly, SF of OA and RA patients has been shown
to contain immunoglobulin G autoantibodies against
BGN, DCN and several other cartilage matrix molecules,
suggesting their release from matrix and subsequent
local loss of immunological tolerance [34]. Immune
complex formation leading to complement and Fcγ re-
ceptor activation plays a role in RA, as well as in OA ac-
cording to recent studies [35–37]. The present finding of
intact sBGN in SF, together with the recognition of
sBGN as an endogenous damage-associated molecular
pattern-type ligand for TLR2/TLR4 and for P2X7/4, pro-
vides a third mechanism of relevance for autoinflamma-
tion, co-stimulation and autoimmunity.
Chondrocytes of OA cartilage are equipped with a full
palette of TLRs, including TLR2 and TLR4, and the pro-
portion of TLR+ chondrocytes increases with progres-
sion of OA [38]. The results of the present study show
that sBGN regulates TLR4 expression to an extent
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similar to that of LPS, which is a known TLR2/TLR4 lig-
and. The effects of sBGN were not caused by LPS con-
tamination, as the result of the endotoxin test was
negative and polymyxin B did not have any effect on the
results in HEK-hTLR4 cells or in primary chondrocytes.
Thus, sBGN can be conceived of as an endogenous
damage-associated molecular pattern, a cartilage-derived
LPS mimic. The mechanism of action of sBGN and
DCN is mediated through activation of TLR4 and the
NF-κB pathway. This is supported by several lines of
(See figure on previous page.)
Fig. 7 CLI-095 abrogates soluble biglycan (sBGN)– and lipopolysaccharide (LPS)–induced Toll-like receptor 4 (TLR4) signalling with CLI-095 in primary
chondrocytes. a Pre-incubation with CLI-095 before sBGN and LPS stimulation abrogated the increase in TLR4 messenger RNA (mRNA) expression.
b A minor increase in catabolic factor mRNA expression occurred when primary chondrocytes were treated with CLI-095 before sBGN and LPS stimulation.
c Blocking TLR4 signalling with CLI-095 inhibited the sBGN-induced upregulation of aggrecan (ACAN or ADAMTS) and collagen type II (COL2A1) before
stimulation. d Production of nitric oxide is reduced by CLI-095 incubation before sBGN or LPS stimulation. All in vitro experiments were technically repeated
at least four times with primary chondrocytes (obtained from one biological sample). Differences between mean values were compared using Student’s
t test, assuming normal distribution where four replicates were used. #p< 0.05, ##p< 0.01, ###p< 0.001 for pairwise comparisons between CLI-095 pre-
incubated and non-CLI-095 pre-incubated sBGN or LPS stimulation. CTSK cathepsin K, MMP matrix metalloproteinase
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evidence. In HEK-hTLR4, which can be activated only
through TLR4, sBGN and sDCN induced the secretion
of AP, a reporter of NF-κB activation. This increase was
significantly inhibited by CLI-095, an inhibitor of TLR4
signalling. Furthermore, in primary chondrocytes, sBGN
induced production of NO, which was almost com-
pletely impaired by CLI-095, an inhibitor of TLR4 sig-
nalling, and also by TLR4-neutralising antibody. In
contrast, addition of TLR2 antibody had no significant
effect on sBGN-induced NO production (Fig. 8). The
signalling of TLR4 has been shown to occur via NF-κB,
which in turn is the principal inducer of iNOS [39, 40].
Furthermore, NO has been implicated as an important
pro-inflammatory mediator of inflammation in OA [41, 42].
Thus, the sBGN induction of secreted AP in HEK-hTLR4
cells and the NO production in chondrocytes suggests that
sBGN can induce a chondrocyte-mediated inflammatory
response in cartilage.
sBGN has been shown in earlier in vitro experiments
to exert dose-dependent effects at least up to 80 μg/ml
concentration on peritoneal macrophages [43]. Although
sBGN concentrations used in vitro are somewhat higher
than those now measured in SF, they are probably
pathophysiologically relevant. Given the fact that BGN is
a pericellular matrix proteoglycan, local concentrations
in the vicinity of chondrocytes can be expected to be
higher than in SF [44]. Moreover, lack of biomechanic-
ally cyclic compression of the cartilage explants causes a
drop in interstitial fluid pressure, and therefore higher
doses of sBGN are needed to ensure outside-in access.
Nevertheless, current in vitro techniques cannot mimic
in vivo conditions, and therefore the next step would be
to replicate the findings of the present study in an OA
animal model.
Interaction of sBGN with TLR4 (and possibly to a
lesser extent the other sBGN receptor, P2X7/4) led to in-
creased production of aggrecanases and collagenolytic
enzymes at the mRNA and protein levels [45]. After
cleavage across the collagen triple helix, fragments
undergo spontaneous helix-to-coil transition to gelatin
at body temperature. Thus, the sBGN-induced proteo-
glycanases (ADAMTS-4/5), collagenases (MMP-13, cat K)
and gelatinases (MMP-9) are able to degrade all the major
components of the hyaline articular cartilage. The ob-
served elevated production of IL-6 and IL-8 levels induced
by sBGN in chondrocytes may also lead to increase re-
cruitment and influx of inflammatory cells such as neutro-
phils and macrophages [46, 47]. Together the observed
levels of MMPs and cytokines add further molecular stress
to the OA joint and might create positive feedback loop of
inflammation and cartilage degradation.
Soluble BGN induced expression of proteinases clearly
more effectively in grade I than in grade IV OA. Grade
IV OA represents an advanced stage of the disease and
the low response of grade IV OA to sBGN could repre-
sent functio laesa (i.e., function disturbed as a result of
inflammation and loss of cartilage). Interestingly BGN
mRNA is more upregulated in advanced OA compared
with early stages suggesting in fact that desensitisation
to BGN in grade IV OA explants may have occurred due
to long term exposure at the pericellular lacunae or by
an attempt of the cartilage to compensate the proteogly-
can loss [22]. In addition, TLR4 upregulation by sBGN
was substantially higher in grade I OA vs grade IV OA.
Thus as expected TLR4-mediated NF-κB pathway prod-
ucts (i.e. proteinases and aggrecanases) were also pro-
portionally upregulated. Likewise NO, a product of
iNOS which is regulated by NF-κB pathway, was also in-
creased in grade I OA vs. grade IV OA.
In primary chondrocytes sBGN inhibited synthesis of the
collagen (fibre network) and aggrecans (ground substance).
In relatively well preserved grade I OA explants sBGN had
a slight stimulatory effects on matrix synthesis, whereas in
more advanced grade IV OA Col-II synthesis decreased sig-
nificantly. Such an imbalance between degradation and syn-
thesis results in a net loss of cartilage [48, 49].
Due to their potential destructive properties, proteolytic
enzymes are tightly regulated. ADAMTS-4/ADAMTS-5
and MMPs are regulated on the transcriptional level (e.g.,
by sBGN), as shown in the present study. They are synthe-
sised as latent pro-enzymes, which for activation require
proteolytic removal of the activation (pro)peptide [50, 51].
The MMPs are regulated by tissue inhibitors of metallopro-
teinases. Therefore, the most direct way to demonstrate
sBGN-induced proteolysis of cartilage is to demonstrate a
release of proteoglycan and collagen degradation products.
This was done by using GAG and collagen-binding dyes
and light absorption. Proteoglycan release was statistically
significant only in grade I OA, as expected given the sub-
stantially higher catabolic response by grade I OA chondro-
cytes. In contrast, collagen release was significant only in
type IV OA, perhaps because collagen becomes accessible
for collagenolytic enzymes only after proteoglycan deple-
tion [52]. Release of proteoglycans was confirmed by stain-
ing, which revealed their depletion from cartilage matrix in
partly overlapping samples.
Conclusions
We demonstrate that intact sBGN is present in knee SF of
patients with advanced knee OA or RA, whereas only low
amounts of sDCN could be detected. sBGN upregulates
TLR4 expression in chondrocytes, increases the expression
and concentration levels of catabolic factors and decreases
the expression of anabolic factors, resulting in net loss of
cartilage. The mechanism of action of sBGN in chondro-
cytes is mediated mainly through activation of TLR4.
These results support the importance TLR4 signalling in
OA pathomechanisms, and thus TLR4 may be a potential
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therapeutic target in inflammation- and catabolism-
mediated cartilage degenerative disorders. Importantly,
our findings strongly support the role of sBGN, a major
ECM protein, as a potential biomarker, therapeutic target
and contributor in the catabolic events that occur during
progression of OA.
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